Politics & Government
FDA Approves Kennesaw Company's New Device
It will eliminate the need for temporary dialysis catheters, which are associated with increased risk of infection.

Good news for patients with end-stage renal disease who are on dialysis.
CryoLife Inc. of Kennesaw announced this week that the U.S. Food and Drug Administration has received clearance for a new HeRO device. The device is used in patients who have blocked central veins.
"The current generation includes a standard ePTFE graft, which requires the placement of a temporary dialysis catheter for approximately 2-3 weeks until the graft incorporates into the surrounding tissue and can be used for hemodialysis access," the company said in a news release.
Find out what's happening in Kennesawfor free with the latest updates from Patch.
The new version features an adaptor that allows physicians to pair the HeRO device with other available dialysis access grafts, including early access arterial grafts.
"Early access grafts eliminate the need for temporary dialysis catheters, which are associated with increased risk of infection," CryoLife chairman, president and CEO Steven G. Anderson said.
Find out what's happening in Kennesawfor free with the latest updates from Patch.
CryoLife anticipates launching the device during the fourth quarter of the year, the company said in the news release.
Get more local news delivered straight to your inbox. Sign up for free Patch newsletters and alerts.